P Michael Conn

List of Publications by Year
in descending order

52 papers	2,734 citations	159525 30 h-index	175177 52 g-index
54 all docs	54 docs citations	54 times ranked	1716 citing authors

#	Article	IF	Citations
1	Pharmacologic Rescue of Conformationally-Defective Proteins: Implications for the Treatment of Human Disease. Traffic, 2004, 5, 821-837.	1.3	241
2	G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo. Pharmacological Reviews, 2007, 59, 225-250.	7.1	225
3	Rescue of Hypogonadotropic Hypogonadism-Causing and Manufactured GnRH Receptor Mutants by a Specific Protein-Folding Template: Misrouted Proteins as a Novel Disease Etiology and Therapeutic Target. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3255-3262.	1.8	182
4	Quality Control Autophagy Degrades Soluble ERAD-Resistant Conformers of the Misfolded Membrane Protein GnRHR. Molecular Cell, 2014, 54, 166-179.	4.5	137
5	Structure-Activity Relations of Successful Pharmacologic Chaperones for Rescue of Naturally Occurring and Manufactured Mutants of the Gonadotropin-Releasing Hormone Receptor. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 608-614.	1.3	131
6	Human Loss-of-Function Gonadotropin-Releasing Hormone Receptor Mutants Retain Wild-Type Receptors in the Endoplasmic Reticulum: Molecular Basis of the Dominant-Negative Effect. Molecular Endocrinology, 2004, 18, 1787-1797.	3.7	100
7	Dominant-Negative Action of Disease-Causing Gonadotropin-Releasing Hormone Receptor (GnRHR) Mutants: A Trait That Potentially Coevolved with Decreased Plasma Membrane Expression of GnRHR in Humans. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3360-3367.	1.8	86
8	Regulation of Gq/11Î± by the Gonadotropin-Releasing Hormone Receptor. Molecular Endocrinology, 1997, 11, 738-746.	3.7	82
9	Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs. Trends in Endocrinology and Metabolism, 2010, 21, 190-197.	3.1	76
10	Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 21030-21035.	3.3	76
11	Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases. Physiological Reviews, 2018, 98, 697-725.	13.1	74
12	Beyond the Signal Sequence: Protein Routing in Health and Disease. Endocrine Reviews, 2005, 26, 479-503.	8.9	71
13	Regulation of G Protein-coupled Receptor Trafficking by Inefficient Plasma Membrane Expression. Journal of Biological Chemistry, 2006, 281, 8417-8425.	1.6	68
14	Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine. Molecular and Cellular Endocrinology, 2009, 298, 84-88.	1.6	68
15	A Novel Mouse Model of Hypogonadotrophic Hypogonadism: N-Ethyl-N-Nitrosourea-Induced Gonadotropin-Releasing Hormone Receptor Gene Mutation. Molecular Endocrinology, 2005, 19, 972-981.	3.7	64
16	Protein Origami: Therapeutic Rescue of Misfolded Gene Products. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2002, 2, 308-316.	3.4	58
17	Protein Folding as Posttranslational Regulation: Evolution of a Mechanism for Controlled Plasma Membrane Expression of a G Protein-Coupled Receptor. Molecular Endocrinology, 2006, 20, 3035-3041.	3.7	57
18	Drug development and the cellular quality control system. Trends in Pharmacological Sciences, 2009, 30, 228-233.	4.0	56

#	Article	IF	Citations
19	Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease. Molecular and Cellular Endocrinology, 2009, 299, 137-145.	1.6	51
20	Unexpected Effects of Epitope and Chimeric Tags on Gonadotropin-Releasing Hormone Receptors: Implications for Understanding the Molecular Etiology of Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 6107-6112.	1.8	50
21	Molecular Mechanism of Action of Pharmacoperone Rescue of Misrouted GPCR Mutants: The GnRH Receptor. Molecular Endocrinology, 2009, 23, 157-168.	3.7	49
22	Misrouted cell surface GnRH receptors as a disease aetiology for congenital isolated hypogonadotrophic hypogonadism. Human Reproduction Update, 2004, 10, 177-192.	5.2	47
23	Parallel Regulation of Membrane Trafficking and Dominant-negative Effects by Misrouted Gonadotropin-releasing Hormone Receptor Mutants. Journal of Biological Chemistry, 2005, 280, 24506-24514.	1.6	44
24	Refolding of misfolded mutant GPCR: Post-translational pharmacoperone action in vitro. Molecular and Cellular Endocrinology, 2007, 272, 77-85.	1.6	44
25	Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function. Molecular and Cellular Endocrinology, 2014, 382, 411-423.	1.6	44
26	â€˜Effective inefficiencyâ€™: cellular control of protein trafficking as a mechanism of post-translational regulation. Journal of Endocrinology, 2006, 190, 13-16.	1.2	42
27	Dominant negative effects of human follicle-stimulating hormone receptor expression-deficient mutants on wild-type receptor cell surface expression. Rescue of oligomerization-dependent defective receptor expression by using cognate decoys. Molecular and Cellular Endocrinology, 2010, 321, 112-122.	1.6	40
28	Salt bridge integrates GPCR activation with protein trafficking. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4454-4458.	3.3	32
29	Therapeutic Rescue of Misfolded Mutants: Validation of Primary High Throughput Screens for Identification of Pharmacoperone Drugs. PLoS ONE, 2011, 6, e22784.	1.1	32
30	Combined Modification of Intracellular and Extracellular Loci on Human Gonadotropin-Releasing Hormone Receptor Provides a Mechanism for Enhanced Expression. Endocrine, 2000, 13, 401-407.	2.2	31
31	Transitioning pharmacoperones to therapeutic use: In vivo proof-of-principle and design of high throughput screens. Pharmacological Research, 2014, 83, 38-51.	3.1	29
32	High-Throughput Screen for Pharmacoperones of the Vasopressin Type 2 Receptor. Journal of Biomolecular Screening, 2013, 18, 930-937.	2.6	28
33	Assay strategies for identification of therapeutic leads that target protein trafficking. Trends in Pharmacological Sciences, 2015, 36, 498-505.	4.0	26
34	Transcriptional Regulation of the Gonadotropin-Releasing Hormone Receptor Gene Is Mediated in Part by a Putative Repressor Element and by the Cyclic Adenosine 3â€²,5â€²-Monophosphate Response Element*. Endocrinology, 1999, 140, 3452-3458.	1.4	23
35	Mice Harboring Gnrhr E90K, a Mutation that Causes Protein Misfolding and Hypogonadotropic Hypogonadism in Humans, Exhibit Testis Size Reduction and Ovulation Failure. Molecular Endocrinology, 2012, 26, 1847-1856.	3.7	22
36	Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus. Journal of Biomolecular Screening, 2016, 21, 824-831.	2.6	20

#	Article	IF	Citations
37	Molecular Cloning and Expression of Two Type One Somatostatin Receptors in Goldfish Brain. Endocrinology, 1999, 140, 5211-5219.	1.4	19
38	Therapeutic Rescue of Misfolded/Mistrafficked Mutants. Methods in Enzymology, 2013, 521, 3-16.	0.4	18
39	Transcriptional Activation of Gonadotropin-Releasing Hormone (GnRH) Receptor Gene by GnRH and Cyclic Adenosine Monophosphate. Endocrinology, 1998, 139, 3896-3902.	1.4	16
40	Salt Bridges Overlapping the Gonadotropin-Releasing Hormone Receptor Agonist Binding Site Reveal a Coincidence Detector for G Protein-Coupled Receptor Activation. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 430-442.	1.3	15
41	Conformational effects of Lys191 in the human GnRH receptor: mutagenesis and molecular dynamics simulations studies. Journal of Endocrinology, 2009, 201, 297-307.	1.2	14
42	A Phenotypic High Throughput Screening Assay for the Identification of Pharmacoperones for the Gonadotropin Releasing Hormone Receptor. Assay and Drug Development Technologies, 2014, 12, 238-246.	0.6	14
43	Drug Library Screening for the Identification of Ionophores That Correct the Mistrafficking Disorder Associated with Oxalosis Kidney Disease. SLAS Discovery, 2017, 22, 887-896.	1.4	14
44	Measurement of Blood Volume in Adult Rhesus Macaques (Macaca mulatta). Journal of the American Association for Laboratory Animal Science, 2015, 54, 687-93.	0.6	14
45	â€œPharmacoperoneâ€: What's in a word?. Pharmacological Research, 2014, 83, 1-2.	3.1	13
46	Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias. PLoS ONE, 2017, 12, e0181830.	1.1	12
47	Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules. Current Drug Targets, 2016, 17, 1471-1481.	1.0	12
48	Gonadotropin-releasing hormone receptor concentration differentially regulates intracellular signaling pathways in GGH3 cells. Pituitary, 1999, 2, 181-190.	1.6	11
49	Pharmacoperone Identification for Therapeutic Rescue of Misfolded Mutant Proteins. Frontiers in Endocrinology, 2011, 2, .	1.5	11
50	Receptor antagonism/agonism can be uncoupled from pharmacoperone activity. Molecular and Cellular Endocrinology, 2016, 434, 176-185.	1.6	11
51	Rescue of Misrouted GnRHR Mutants Reveals Its Constitutive Activity. Molecular Endocrinology, 2012, 26, 1179-1188.	3.7	10
52	Pharmacoperones: targeting therapeutics toward diseases caused by protein misfolding. Revista De Investigacion Clinica, 2015, 67, 15-9.	0.2	3